Zenas BioPharma – Talk Bio

Zenas BioPharma Secures $300M Royalty Deal for Obexelimab FDA Approvals

1 week ago talkbio0Tagged Approved, Autoimmune Diseases, IgG4-Related Disease, Lupus Erythematosus, Systemic, Obexelimab, Phase 3 INDIGO trial, Royalty, Royalty Pharma, United States Food and Drug Administration, Zenas BioPharma

Zenas BioPharma; Royalty Pharma; Obexelimab; autoimmune diseases; IgG4-Related Disease; Systemic Lupus Erythematosus; FDA approval; royalty agreement; Phase 3 INDIGO trial; funding

Biotech IPO Market Sees Rare Upsurge with Triple Listing Success

12 months ago talkbio0Tagged Bicara Therapeutics, Biosciences, biotech, Drug Industry, Flux, IPO, Market, MBX, Stock Surge, Tripleheader, Zenas BioPharma

Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry

Bicara and Zenas File for IPOs to Advance Late-Phase Cancer and Autoimmune Treatments

1 year ago talkbio0Tagged Autoimmune Diseases, Bicara, Cancer Therapeutic Procedure, IPO, Zenas BioPharma

Bicara Therapeutics, Zenas BioPharma, IPO, cancer treatment, autoimmune disease, biotech, pharmaceuticals